Current Report Filing (8-k)
December 05 2016 - 8:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported):
December 5, 2016
LIPOCINE INC.
(Exact name of registrant as specified in
its charter)
Commission File No. 001-36357
Delaware
|
|
99-0370688
|
(State or other jurisdiction of incorporation)
|
|
(IRS Employer Identification Number)
|
675 Arapeen Drive, Suite 202
Salt Lake City, Utah 84108
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including
area code:
(801) 994-7383
Former name or former address, if changed
since last report:
Not Applicable
______________________
Check the appropriate box below if the Form
8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 7.01
Regulation FD Disclosures
On December 5, 2016, Lipocine Inc. issued a press release announcing
the initiation of a dosing validation study for LPCN 1021. The press release is filed as Exhibit 99.1 and is incorporated herein
by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The following exhibits are filed with this report:
Exhibit No.
|
Description
|
|
|
99.1
|
Press Release Announcing the Initiation of the Dosing Validation Study for LPCN 1021
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
LIPOCINE INC.
|
|
|
|
|
|
|
|
|
|
|
Date:
|
December 5, 2016
|
|
By:
|
/s/ Mahesh V. Patel
|
|
|
|
|
Mahesh V. Patel
|
|
|
|
|
President and Chief Executive Officer
|
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Sep 2023 to Sep 2024